Day 24 November 2021

FDA updates on possible mitigation strategies to reduce the risk of nitrosamine drug substance-related impurities in drug products

The FDA has recently updated its information on possible mitigation strategies to reduce the risk of nitrosamine drug-substance related impurities in drug products (NDSRIs). Guidance for industry on nitrosamine was published in September 2020 and updated in February 2021. A…

Read MoreFDA updates on possible mitigation strategies to reduce the risk of nitrosamine drug substance-related impurities in drug products